BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:XBiotech readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies XBiotech's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06590090-6351@assetmemo.bio
DTSTAMP:20261121T005437Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Natrunix: Phase 2 readout est. (NCT06590090)
DESCRIPTION:Natrunix\, phase 2\, Rheumatoid Arthritis.\nStudy: Natrunix in 
 Combination With Methotrexate for Rheumatoid Arthritis Treatment\nEstimate
 d primary completion: 15 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/natrunix#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06590090
URL:https://assetmemo.bio/drug/natrunix#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
